This arm will consume 2 portions (each 200 g cooked) of conventional fish (sea bream) fillet per week for a 1-month period.

This arm will consume 2 portions (each 200 g cooked) of fish fillet bred with bioactive lipids from olive oil by-products per week for a 1-month period.

Cardiometabolic Health

Participants initially randomized to this intervention arm will be provided with a total of 8 conventional sea bream fillets and will be asked to consume them twice weekly for 1 month. Sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to avoid the reception of any medication or dietary supplement and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.

Conventional sea bream

Participants initially randomized to this intervention arm will be provided with a total of 8 enriched sea bream fillets, and will be asked to consume them twice weekly for 1 month. Enriched sea bream fillets will be produced by a fish farming company from fish bread with a fraction of bioactive polar lipids extracted from olive oil by-products. Participants will also be instructed to avoid the reception of any medication or dietary supplement and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.

Enriched sea bream

Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University

Cardioprotective Properties of ELAIOTSIPOURA

Cardioprotective Properties of Sea Bream Bred With a Fraction of Polar Lipids Extracted From Olive Oil By-products: the ELAIOTSIPOURA Study

Efficiency concentration fifty of adenosine diphosphate-induced platelet aggregation (microM) will be assessed by light transmittance aggregometry

Efficiency concentration fifty of platelet activating factor-induced platelet aggregation (microM) will be assessed by light transmittance aggregometry

Tissue plasminogen activator activity (mIU/mL) will be measured in blood samples using commercially available ELISA kits

Plasminogen activator inhibitor-1 activity (mAU/mL) will be measured in blood samples using commercially available ELISA kits

High-sensitivity interleukin-6 levels (pg/mL) will be measured in blood samples using commercially available ELISA kits

High-sensitivity interleukin-10 levels (pg/mL) will be measured in blood samples using commercially available ELISA kits

Soluble P-selectin levels (ng/mL) will be measured in blood samples using commercially available ELISA kits

Deidentified individual participant data will be shared to investigators for the purpose of individual participant data meta-analysis, provided that the proposed use of the data has been approved by the Study Principal Investigator. Proposals should be directed to antonop@hua.gr. To gain access, data requestors will need to sign a data access agreement.

Smaragdi Antonopoulou

Professor in Biochemistry

Harokopio University

Nireus Aquaculture

University of Thessaly

Cretan Herbalchem S.A.

National and Kapodistrian University of Athens

European Regional Development Fund (project code: T1EDK- 00687)

standard medical treatment (care as usual) with supportive talks

weekly sessions of gut focused hypnotherapy in groups (10 sessions within 12 weeks)

Irritable Bowel Syndrome

weekly session (45 min) of gut focused hypnotherapy (10 sessions within 12 weeks)

Gut-focused hypnotherapy in group sessions

Group Hypnosis for Irritable Bowel Syndrome

GUT-FOCUSED GROUP HYPNOSIS FOR TREATMENT OF IRRITABLE BOWEL SYNDROME - A RANDOMISED CONTROLLED TRIAL

the IBS-Impact-Scale (IBS-IS). The IBS-IS is a disease-specific documentation of the impact of IBS on patients' lives and was developed and validated for use in clinical trials

conveys eight dimensions of Quality of life (QOL): limitations in physical functioning, role limitation due to physical health problems, bodily pain, general health perception, vitality, social functioning, role limitations due to emotional limitations and mental health (higher scores indicating higher QOL). Validity and reliability have been proven extensively for diverse patient groups

Gabriele Moser

ao.Univ.Prof.Dr.med.

Medical University of Vienna

Personalized diet added with quinoa and flaxseed

Personalized diet without dietary supplement

Metabolic Syndrome

Nutritional and Metabolic Diseases

Quinoa

Flaxseed

personalized diet added with quinoa and flaxseed

Quinoa and Flaxseed

Epidemiología y determinantes sociales asociados a la obesidad y la diabetes tipo 2 en México

NORMA Oficial Mexicana NOM-037-SSA2-2012, Para la prevención, tratamiento y control de las dislipidemias.

Diferencias entre la prevalencia de obesidad y exceso de peso estimadas con datos declarados o por medición directa en adultos de la Comunidad Valenciana

Consumer Acceptability of Muffins with Flaxseed (Linum usitatissimum)

Flavonoids and other phenolic compounds in Andean indigenous grains: Quinoa (Chenopodium quinoa), kañiwa (Chenopodium pallidicaule) and kiwicha (Amaranthus caudatus)

Nutraceuticals and Functional Foods in Health Promotion and Disease Risk Reduction

Inhibition of reverse transcriptases by flavonoids

Utilidad de la Prueba de Micronúcleos y Anormalidades Nucleares en Células Exfoliadas de Mucosa Oral en la Evaluación de Daño Genotóxico y Citotóxico

Procedimientos básicos de la prueba de micronúcleos y anormalidades nucleares en células exfoliadas de mucosa oral

Una nueva definición mundial del síndrome metabólico propuesta por la Federación Internacional de Diabetes: fundamento y resultados

Hospital Civil de Guadalajara "Fray Antonio Alcalde"

Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara

Efect of Quinoa and Flaxseed in Cititoxicity and Glicemic Control in Metabolic Syndrome Patients

Evaluation of the Citotoxicity and Clicemic Control of Subject With Metabolic Syndrome Managed With Conventional Nutritional Tratment More Quinoa, Flaxseed or Borh Versus Conventional Nutrition

The number of micronuclei will be evaluated at baseline at 12 weeks and 24 weeks with Schmidt technique by Giemsa/wright and the entered values reflect the number of micronuclei at week 24

The fasting glucose levels will be evaluated at baseline, at 12 weeks and 24 weeks with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at 24 weeks

Glycosylated hemoglobin will be evaluated at baseline, at 12 weeks and 24 weeks by high-pressure liquid chromatography (HPLC) and the entered values reflect the glycosylated hemoglobin at 24 weeks

The body weight will be measured at baseline, at 12 weeks and 24 weeks with a bioimpedance balance and the entered values reflect the body weight at 24 weeks

Body Mass Index will be calculated at baseline, 12 weeks and 24 weeks with the Quetelet index formula and the entered values reflect the body mass index at 24 weeks

Waist circumference will be evaluated at baseline and at 24 weeks with a flexible tape

Total cholesterol levels will be evaluated at baseline and 24 weeks by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at 24 weeks

Triglycerides levels will be evaluated at baseline and 24 weeks with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at 24 weeks

c-HDL levels will be evaluated at baseline and 24 weeks with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at 24 weeks

c-LDL levels will be evaluated at baseline and 24 weeks with enzymatic/colorimetric techniques and the entered values reflect the c-LDL level at 24 weeks

Blood pressure will be measured at baseline and 24 weeks with a digital sphygmomanometer and the entered values reflect the blood pressure at 24 weeks

El uso de los datos es exclusivo de los investigadores involucrados en el estudio sin la devulgacion de los mismos a terceros externos al equipo de trabajo

sea/antidepresan

Cardioprotective Properties of ELAIOTSIPOURA

Group Hypnosis for Irritable Bowel Syndrome

Efect of Quinoa and Flaxseed in Cititoxicity and Glicemic Control in Metabolic Syndrome Patients

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı